摘要
目的观察膀胱癌组织中趋化因子受体CXCR7的表达变化及意义。方法收集37例膀胱癌患者的癌组织(观察组)和29例癌旁正常组织(对照组),采用逆转录聚合酶链反应法(RT-PCR)和免疫组化法分别检测其中的CXCR7 mRNA和蛋白。结果观察组CXCR7 mRNA相对表达量为0.692±0.071,明显高于对照组的0.432±0.148,P<0.05。观察组中浅表性膀胱癌CXCR7 mRNA相对表达量为0.676±0.065,明显低于浸润性膀胱癌组织中的0.731±0.074,但二者均高于对照组,P均<0.05。观察组11例CXCR7蛋白低表达、26例高表达,对照组分别为23、6例,两组CXCR7蛋白表达情况相比P<0.05。观察组26例浅表性膀胱癌中15例CXCR7高表达,11例浸润性膀胱癌CXCR7均为高表达。CXCR7表达情况与膀胱癌临床分期有关(P<0.05)。CXCR7表达情况与膀胱癌患者年龄、性别无关(P均>0.05)。结论膀胱癌组织中CXCR7 mRNA和蛋白表达升高。检测膀胱癌组织中的CXCR7 mRNA或蛋白可能有助于判断膀胱癌的临床分期。
Objective To investigate the expression and clinical significance of CXCR7 in bladder carcinoma. Methods The expression of CXCR7 mRNA and protein were detected by RT- PCR and immunohistochemistry in bladder carcinoma tissues from 37 patients and para cancerous tissues from 29 patients. Results The expression of CXCR7 mRNA in the observation group was 0. 692 ± 0.071, significantly higher than that in the control group (0. 432 ±0. 148 ), P 〈 0.05. In the observation group, the expression of CXCR7 mRNA in superficial bladder cancer was 0.676 ±0.065, significantly lower than the invasive bladder cancer(0.731 ±0.074), but both were higher than those in the control group, and both P 〈 0.05. In the observation group, there were 11 cases with high expression and 26 cases with low expression of CXCR7 protein, while there were 23 cases and 6 cases in the control group. There were 15 patients with high expression of CXCR7 in 26 ones of superficial tissues bladder cancer in the observation group. Then 011 CXCR7 protein in 11 cases of invasive bladder cancer were high expressed. So CXCR7 expression was relative to clinical stage ( P 〈 0.05 ). And it was independent to age, sex of bladder cancer patients. Conclusions The expression of CXCR7 mRNA and protein in bladder cancer tissues is high. It may be helpful to decide the Clinical stage of bladder carcinoma with the method of detecting the CXCR7 mRNA and protein in bladder caner tissues.
出处
《山东医药》
CAS
北大核心
2011年第50期22-24,共3页
Shandong Medical Journal
关键词
膀胱肿瘤
膀胱癌
趋化因子受体
bladder neoplasms
bladder carcinoma
chemokine recepter